Submit Your Feeds

Business News • PR NewsWire • Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD

Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD
Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD

BOSTON, Oct. 30 /PRNewswire/ -- Tibotec Pharmaceuticals (Tibotec) announced today the company will present the results of a Week-24 planned interim analysis of the phase 2 response-guided PILLAR study in treatment-naive patients with chronic genotype 1 hepatitis C virus (HCV) at the 61st Annual Meet

View More : http://www.prnewswire.com/news-releases/week-24-interim-results-from-phase-2b-pillar-study-to-be-presented-as-late-break...
Releted News by prnewswire
Achieving Sustained Viral Response for Patients with Recurrent Hepatitis C After Transplantation is Key for Long-Term Outcomes
MAN ON A LEDGE Begins Principal Photography
IndiaMART.com to Represent Indian SMEs in the US
Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD
Home Sitemap Contact Us
© businessNewsNewsNews.com